1. A pharmaceutical composition for use in treating skin scar in a patient in need thereof, comprising a therapeutic amount of a mitogen-activated protein kinase inhibitor, activated protein kinase 2 (MK2), containing the YARAAARQARAKALARQLGVAA amino acid sequence polypeptide inhibitor MK2 (SEQ ID NO: 1) or its functional equivalent, and a pharmaceutically acceptable carrier, where a patient in need thereof suffers from a wound, an iterative amount is effective (a) to reduce prevalence, t tin or both of the skin scar without impairing normal healing of the wound and (b) for treating the patient’s skin scar in such a way that at least one of the following is reduced in comparison with the control: the size of the wound, the wound area and the formation of turns collagen in the wound. 2. The pharmaceutical composition of claim 1, wherein the wound is a scratch, laceration, crushed wound, closed injury, puncture wound, tear, burn, ulcer, surgical wound, sprain, or combinations thereof. The pharmaceutical composition according to claim 1, wherein the skin scar is a pathological scar, postoperative scar, or a combination thereof. The pharmaceutical composition according to claim 3, wherein the pathological scar is selected from the group consisting of hypertrophic scar, keloid scar, atrophic scar, cicatricial contracture, or a combination thereof. The pharmaceutical composition according to claim 3, wherein the pathological scar is the result of a distension located in the immediate vicinity of the joint, including the knee, elbow, wrist, shoulder, hip, spinous process, or a combination thereof.1. Фармацевтическая композиция для использования при лечении кожного рубца у пациента, нуждающегося в этом, содержащая терапевтическое количество ингибитора митоген-активированной протеинкиназы - активированной протеинкиназы 2 (MK2), содержащей полипептидный ингибитор MK2 аминокислотной последовательности YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) или его функциональный эквивалент, и ф
